Iroquois Capital Group

RS Metrics, established in 2013, specializes in providing asset-level environmental, climate, and physical risk metrics using satellite imagery and geospatial analytics technology. The company offers two primary products: ESGSignals® and AssetTracker. These products leverage a model-driven architecture, along with artificial intelligence, machine learning, and data science expertise to deliver over 100 independent, verifiable, and real-time environmental insights. In 2023, RS Metrics partnered with Google Cloud Platform to democratize access to these metrics via SAAS, DAAS, or Dashboards, enabling stakeholders of all sizes to make informed decisions regarding capital allocation and risk management.

Iroquois Security Monitoring provides security alarm products and services. ISM specializes in managing residential security alarm systems and provides services such as fire alarm, theft alarm, and smoke alarm installations.

Community Care Solutions partners with rural hospitals to implement pain management programs. Community Care Solutions brings pain management and interventional pain management services to community hospitals.

Covenant Physician Partners is a privately-held company that owns and operates ambulatory surgery centers, focusing on providing high-quality surgical care. It specializes in minimally invasive and robotic technologies for procedures related to colorectal cancer screening, polyp removal, and digestive tract surgery. In addition to surgical services, Covenant manages anatomic pathology laboratories and physician practices, offering essential back-office functions such as human resources, billing, contract negotiations, and accounting. This comprehensive support allows healthcare professionals to concentrate on patient care while ensuring efficient operational management within their practices.

ACS Partners is a provider of construction services, focusing on both the commercial and residential sectors. The company specializes in renovations of multi-family complexes, student housing projects, and single-family residential properties. By catering to the needs of various developers, ACS Partners is positioned to deliver tailored construction solutions that enhance living and working environments.

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapeutic products for cancer treatment. The company's lead product candidate, tucatinib, is an oral, HER2-selective small molecule tyrosine kinase inhibitor currently undergoing two Phase Ib clinical trials for metastatic breast cancer in combination therapies. In addition to tucatinib, Cascadian Therapeutics is advancing its preclinical pipeline, which includes CASC-578, a Chk1 cell cycle inhibitor, and CASC-674, an antibody targeting immuno-oncology. The company has established collaborative agreements with Array BioPharma for tucatinib development, Sentinel Oncology for novel Chk1 inhibitors, and Adimab for discovering new antibodies targeting immunotherapy in oncology. Founded in 1985 and formerly known as Oncothyreon Inc., Cascadian Therapeutics continues to focus on providing targeted therapies that aim to improve cancer treatment outcomes.

Raptor Pharmaceuticals Corp. is a development stage biotechnology company based in Novato, California, focused on discovering and developing innovative drug candidates for various serious conditions, including brain disorders, neurodegenerative diseases, genetic disorders, and cancers. The company is advancing several clinical-stage products, including DR Cysteamine, which is undergoing Phase IIb trials for nephropathic cystinosis and Phase IIa trials for non-alcoholic steatohepatitis, as well as Convivia for ALDH2 deficiency and additional candidates targeting Huntington's disease and migraine. Raptor is also engaged in preclinical development of therapies such as HepTide for hepatocellular carcinoma, WntTide for breast cancer, and NeuroTrans for neurodegenerative diseases. The company collaborates with academic institutions, including the University of California, San Diego, to enhance its research and clinical studies. Founded in 2005, Raptor Pharmaceuticals is dedicated to developing bio-pharmaceutical therapies aimed at treating debilitating and life-threatening diseases.

Soligenix, Inc., a late-stage biopharmaceutical company based in Princeton, New Jersey, focuses on developing and commercializing treatments for rare diseases and serious side effects of cancer therapies, where there is an unmet medical need. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops therapies such as SGX301 for cutaneous T-cell lymphoma, SGX942 for oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone for gastrointestinal disorders. The Public Health Solutions segment works on biodefense vaccines and therapeutics, including RiVax, a ricin toxin vaccine, and SGX943, a therapeutic candidate for antibiotic-resistant and emerging infectious diseases.

TapImmune engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAP cancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops vaccines for infectious diseases using its TAP gene technology. TapImmune has strategic relationships with University of British Columbia, Crucell Holland B.V., SAFC Pharma, Inc., and National Institute of Allergy and Infectious Diseases. The company was founded in 1999 and is based in Vancouver, Canada.

Sevion Therapeutics is a biopharmaceutical company focused on discovering, developing, and acquiring innovative product candidates for the treatment of cancer and immunological diseases. The company advances a diverse pipeline of proprietary and partnered product candidates, leveraging its unique antibody technology platforms. These technologies enable the discovery of innovative biologic therapies targeting previously inaccessible areas, such as multispanning membrane proteins and ion channels, which are critical in various diseases. Additionally, Sevion has developed a pioneering protein nanocage system designed for the delivery of nucleic acids and other therapeutic payloads to specific target cells, enhancing the potential for effective treatment options in human therapeutic applications.

Biomoda, Inc. is an in-vitro diagnostics company focused on developing assays for cancer detection, particularly early-stage lung cancer. Founded in 1990 and headquartered in Albuquerque, New Mexico, Biomoda is advancing its proprietary CyPath assay, which utilizes a patented porphyrin application to identify cancerous cells in deep-lung sputum samples. The company is also expanding its research to create diagnostic solutions for various other cancers, including breast, oral, prostate, bladder, colorectal, and cervical cancers. Biomoda collaborates with the New Mexico Institute of Mining and Technology for clinical studies aimed at early lung cancer detection among veterans. Additionally, it has partnered with Medical Acoustics to incorporate their Lung Flute device into its collection protocol. The company is supported in navigating the FDA approval process through contracts with Quintiles Consulting and Alquest, Inc.

SinoHub, Inc. is an electronics company based in Shenzhen, China, that operates globally in two main segments: Integrated Contract Manufacturing (ICM) and Electronic Component Sales and Services (ECSS). The ICM segment specializes in the production of custom, private label mobile phones and tablets, primarily targeting customers in developing countries. Meanwhile, the ECSS segment focuses on the sales of electronic components and offers comprehensive supply chain management services, including procurement, warehousing, logistics, and import/export facilitation for manufacturers and design houses. Additionally, SinoHub provides a proprietary web-based software platform that streamlines the management of electronic component purchases and movement, enhancing efficiency in inventory and order tracking. Founded in 2000, SinoHub serves a diverse clientele that includes contract manufacturers, original equipment manufacturers (OEMs), and electronics manufacturing services (EMS) companies.

VeriTeQ is a technology company based in Delray Beach, Florida, specializing in identification solutions for animals and emergencies. Founded in 1993, the company offers a range of products including FDA-approved implantable microchips for pet identification, visual and radio frequency identification (RFID) ear tags for livestock tracking, and GPS search and rescue beacons designed for use on aircraft, ships, and by outdoor enthusiasts. Additionally, VeriTeQ develops RFID technologies for identifying implantable medical devices utilized in radiation therapy and is creating a data analytics platform aimed at enhancing evidence-based healthcare through the collection of treatment regimen data.

CEL-SCI specializes in developing immunotherapies to combat cancer and infectious diseases. Its flagship product is Multikine, currently in phase III trials for head and neck cancer treatment. The company's proprietary LEAPS technology aims to stimulate the human immune system against various diseases.

Agenus Inc. is a clinical-stage immuno-oncology company focused on the discovery, development, and commercialization of innovative immunotherapies and vaccines for cancer and infectious diseases. Based in Lexington, Massachusetts, the company aims to activate the immune system to recognize and combat cancer cells through a diverse portfolio that includes checkpoint antibodies, tumor microenvironment modifiers, and vaccine adjuvants. Agenus utilizes its proprietary Retrocyte Display platform for antibody discovery and develops a range of therapeutic candidates, including monoclonal antibodies and vaccines targeting various tumor-specific neo-epitopes. The company has several products in clinical trials, including CTLA-4 and PD-1 antagonists, and collaborates with notable partners such as Incyte Corporation and Merck Sharpe & Dohme to advance its immuno-oncology therapies. Founded in 1994, Agenus continues to build its capabilities in research, development, and manufacturing within the field of immunotherapy.

ACE*COMM Corporation was a provider of operations support systems (OSS) and mobile applications for telecommunications service providers and enterprises. Their solutions were designed for wired, wireless, voice, data, multimedia, and Internet communication networks. Operating in various regions including the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific, ACE*COMM established strategic alliances with telecommunication and Internet equipment manufacturers, computer equipment manufacturers, and telecom systems integrators. Founded in 1983 and headquartered in Gaithersburg, Maryland, the company focused on delivering essential tools for efficient network operations and management in the telecommunications industry.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Migo Software, Inc. engages in the development, acquisition, and marketing of software and infrastructure technologies designed for the storage and accession of personalized mobile information. Its flagship product, Migo, allows users to synchronize their personalized computing environments, including email, digital media, and other data; and application settings to portable storage devices, such as flash/hard disk drives, smart phones, and MP3 players. The company also offers XP to Vista Easy-Sync Suite that provides a safety net and applications support for users transitioning their data and computing environment to a new or upgraded computer running Microsoft’s Windows Vista Operating System; Registry Repair, which fixes computer problems, such as system lock-ups and freezes; PC BackUp, a disaster recovery tool that simplifies the computer backup process; and Recover Lost Data, an utility for retrieving files. In addition, it provides Digital Vault/Portable Vault, Digital File Shedder, DriveWasher, and Easy PC Transfer that offer a line of backup, system utility, and online security/privacy for the users. Migo Software sells its products primarily through original equipment manufacture partnerships, resellers, and through its Web site in the United States and internationally. The company was formerly known as Powerhouse Technologies Group, Inc. and changed its name to Migo Software, Inc. in 2006. Migo Software is headquartered in Redwood City, California.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

BravoSolution SpA specializes in supply management technology software and services aimed at enhancing procurement and sourcing processes. The company provides a range of solutions, including Spend Analysis to optimize savings and compliance, eSourcing for collaborative sourcing efforts, and supplier performance management tools. Its Contract Management service streamlines contract processes to ensure users realize savings from their negotiations. Notable products include BravoAlign, a cloud-based procurement alignment solution, and BravoAdvantage, a comprehensive platform that supports procurement initiatives from demand to contract. Additionally, BravoAdvantage Analytics offers data visualization tools, enabling procurement professionals to create intuitive reports and dashboards. BravoSolution also delivers collaboration services and government solutions related to spend visibility and electronic sourcing. Founded in 2000 and headquartered in Milan, Italy, BravoSolution operates offices in multiple countries, including the United States, Brazil, and several European nations. As of late 2017, it functions as a subsidiary of JAGGAER, Inc.

Pharmacopeia, Inc. is a biopharmaceutical company focused on the discovery and development of therapeutics for unmet medical needs. The company's internal program portfolio includes PS433540, a dual-acting angiotensin and endothelin receptor antagonist currently in phase II clinical development for cardiovascular and renal diseases, such as hypertension and diabetic nephropathy. Additionally, PS178990, a muscle selective SARM agonist, is in phase I clinical development. Pharmacopeia also has a preclinical product, PS031291, aimed at treating multiple myeloma and inflammatory diseases like rheumatoid arthritis, as well as JAK3 inhibitors targeting T-cell and cytokine mediated dermatologic and ocular conditions, including psoriasis and dry eye. The company has formed strategic alliances with several pharmaceutical firms, enhancing its research and development capabilities. Founded in 1993 and based in Cranbury, New Jersey, Pharmacopeia was previously known as Pharmacopeia Drug Discovery, Inc. and became a subsidiary of Ligand Pharmaceuticals Inc. in 2008.